CMS Sticks With Combining Biosimilars In Single Medicare Payment Code
This article was originally published in The Pink Sheet Daily
Executive Summary
Biosimilars referencing the same innovator biologic will all be placed into the same billing code for Medicare, CMS says in final rule, despite opposition from biopharma manufacturers and members of Congress.
You may also be interested in...
Biosimilars Payments In Medicare: CMS Signals Willingness To Change
Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.
Biosimilars Payments In Medicare: CMS Signals Willingness To Change
Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.
HHS Action On Drug Pricing: Here's Who Secretary Price Is Listening To
HHS is expected to move ahead with action to address high drug prices following a series of stakeholder roundtables held over the past month.